Related references
Note: Only part of the references are listed.Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy
I. Garassino et al.
BREAST (2009)
The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients
J. Li et al.
EJSO (2008)
Occult axillary node metastases in breast cancer are prognostically significant: Results in 368 node-negative patients with 20-year follow-up
Lee K. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Significance of sentinel lymph node micrometastases in human breast cancer
Charles E. Cox et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Breast cancer patients with micrometastases only: Is a basis provided for tailored treatment?
D. Grabau
SURGICAL ONCOLOGY-OXFORD (2008)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system
Harriette J. Kahn et al.
BREAST JOURNAL (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
A Chagpar et al.
CANCER (2005)
Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement
M Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy
G Viale et al.
ANNALS OF SURGERY (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells
H Takeuchi et al.
CLINICAL CANCER RESEARCH (2004)
Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: A case-control study with 15-year follow-up
B Susnik et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer
A Goldhirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
RT Chlebowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Occult axillary lymph node metastases are of no prognostic significance in breast cancer
RR Millis et al.
BRITISH JOURNAL OF CANCER (2002)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
Share Paper
